Jul 30, 2026
Ontario, Canada – [July 30th, 2026] – Pleryon Therapeutics Ltd. (“Pleryon”), a clinical-stage biotechnology company developing innovative polymer-based therapeutics, today announced the successful completion of Part 1 of its first-in-human (FIH) clinical trial for dry eye disease (NCT07593404).
The study, conducted at the Centre for Ocular Research & Education (CORE) at the University of Waterloo, evaluated the safety and tolerability of Pleryon’s synthetic polymer-based eye drop in dry eye patients. All six participants in Part 1 completed the single dose safety assessment with no significant or serious adverse events reported, supporting continuation to Part 2 of the study.
“We are extremely encouraged by these initial results,” said Dr. Yu Yu, Founder and CEO of Pleryon Therapeutics. “These early signals support our polymer platform’s potential to provide meaningful, sustained relief for dry eye patients.”
The investigational product is a synthetic polymer-based eye drop inspired by the structure of lubricin, which is a natural lubricating protein found on the ocular surface. Leveraging its proprietary polymer platform, Pleryon’s team has engineered a unique solution to provide immediate and sustained boundary lubrication to the ocular surface, addressing ocular discomfort in DED patients.
Based on the successful completion of Part 1, Pleryon anticipates advancing to the next phase of the trial to further evaluate the product’s safety and tolerability over 28 days of twice a day use in a larger cohort.
About Pleryon Therapeutics
Pleryon Therapeutics is a clinical-stage biotechnology company dedicated to addressing high unmet medical needs through a pioneering polymer engineering platform. The company is developing polymer-based therapeutics for conditions including dry eye disease and osteoarthritis. Pleryon is backed by leading life science investors, including Lapam Capital, Kaitai Capital and Efung Capital.
Forward-Looking Statements
This press release contains forward-looking statements, including those regarding product development, safety, potential benefits, and the timing of future clinical trials. Actual results may differ materially due to risks and uncertainties inherent in product development. Pleryon undertakes no obligation to update these statements except as required by law.
Media Contact
Pleryon Therapeutics